CapitolRadar tracks every publicly disclosed LLY trade by US congress members and corporate insiders: 89 disclosed trades (41 buys, 48 sells) by 8 tracked traders, from 2021-03-05 to 2026-09-04. Updated daily from official filings.
Want a ping when Congress buys LLY? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Eli Lilly and Company (LLY) — Healthcare · Drug Manufacturers - General, market cap about $1,113.7B.
CapitolRadar analysis
2 tracked trades, both sales
LLY’s disclosed activity consists of 2 tracked trades from April 15, 2025, through November 21, 2025. Both transactions were sells: 0 buys and 2 sells, made by 2 distinct traders. That produces a 100% sell share within the tracked sample, but the sample is very small. With only 2 transactions and 2 participants, the record describes limited disclosed activity rather than a broad or repeated trading pattern.
1 sale in Q2 and 1 sale in Q4
The transactions were split across two reporting periods. The second quarter of 2025 contained 1 tracked trade and 0 buys. The fourth quarter of 2025 also contained 1 tracked trade and 0 buys. No tracked transactions are listed here for the third quarter, while the supplied period begins during Q2 and ends during Q4. Each represented quarter therefore contributes half of the 2-trade total, and neither quarter includes a purchase.
Disclosure timing limits the read-through
Congressional and insider transaction disclosures can appear up to 45 days after a trade, so the public filing date may lag the underlying transaction and recent activity may not yet be fully visible. Transaction amounts, when reported as ranges, are estimates rather than exact dollar values; no transaction-value figures are included in the supplied facts for LLY. The data also does not provide trader names, sale sizes, holdings before or after the transactions, or stated reasons for selling. Accordingly, the clearest supported observation is narrow: across 2 tracked disclosures for Eli Lilly and Company, a Healthcare company in Drug Manufacturers - General, activity was entirely sell-side, but it came from only 2 traders and remains a small sample.
Analysis written from the tracked record on 2026-08-25; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 1 | 1 | 0 |
| 2026 Q2 | 1 | 1 | 0 |
| 2025 Q4 | 2 | 1 | 1 |
| 2025 Q3 | 2 | 1 | 1 |
| 2025 Q2 | 7 | 4 | 3 |
| 2025 Q1 | 4 | 1 | 3 |
| 2024 Q4 | 13 | 2 | 11 |
| 2024 Q3 | 1 | 0 | 1 |
Who is buying LLY?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Josh Gottheimer | 17 | 2025-05-01 | — |
| Ro Khanna | 14 | 2026-09-04 | — |
| Markwayne Mullin | 4 | 2025-12-29 | — |
| Marjorie Taylor Greene | 4 | 2025-05-14 | — |
| Jared Moskowitz | 2 | 2023-12-28 | — |
Disclosed trades in LLY
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-04 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2026-06-02 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2025-12-29 | Markwayne Mullin | buy | $15,001 - $50,000 | — |
| 2025-11-21 | John Boozman | sell | $1,001 - $15,000 | — |
| 2025-08-26 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2025-07-02 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2025-06-06 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2025-05-14 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-05-13 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2025-05-05 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-05-01 | Josh Gottheimer | buy | $1,001 - $15,000 | — |
| 2025-04-15 | Tommy Tuberville | sell | $15,001 - $50,000 | — |
| 2025-04-09 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2025-03-10 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2025-02-19 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2025-01-21 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-01-08 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2024-12-24 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2024-12-18 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2024-12-16 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
These buyers also bought
Other stocks the tracked buyers of LLY disclosed buying in the last six months: MSFT (3) · GOOGL (2) · META (2) · SNDK (2) · AMD (2) · HCA (2).
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In…
Frequently asked questions
Which politicians bought LLY most?
Josh Gottheimer leads with 17 disclosed buys, followed by Ro Khanna.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.